February 5, 2024: MorphoSys AG, declared that it entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG dependent on Novartis' intention to deliver a voluntary public takeover deal for all of MorphoSys' superior common shares in exchange for money of € 68.00 per share.
January 30, 2024: MorphoSys AG reported preliminary Monjuvi® U.S. net material sales and gross margin for Monjuvi U.S. net product sales for the complete year of 2023 and given its 2024 financial assistance. In this environment, MorphoSys limits its financial liability from the cooperation with its partner Incyte and credits finance income consequently.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?